The success of Mounjaro (tirzepatide) and semaglutide has triggered an unprecedented wave of innovation in metabolic medicine. Pharmaceutical companies worldwide are racing to develop next-generation treatments that promise even greater efficacy, improved convenience, and broader therapeutic applications. Here is what UK patients should watch for.
Oral Formulations
One of the most anticipated developments is the shift from injectable to oral medications:
- Oral semaglutide (Rybelsus) is already available in the UK for type 2 diabetes, though at lower doses than the injectable weight management version
- Oral tirzepatide is in advanced clinical trials, with early results showing comparable efficacy to the injectable form
- Danuglipron (Pfizer) is an oral GLP-1 receptor agonist in development, though it has faced setbacks in trials
Oral formulations could significantly improve patient convenience and acceptance, particularly for those who are needle-averse.
Triple Receptor Agonists
If tirzepatide's dual agonism (GIP + GLP-1) was a leap forward, the next step is triple agonism:
- Retatrutide (Eli Lilly) targets GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trial results showed up to 24% body weight reduction at 48 weeks — potentially surpassing tirzepatide
- Survodutide (Boehringer Ingelheim) is a dual GLP-1/glucagon agonist showing promising results for both weight loss and fatty liver disease
Muscle-Sparing Approaches
A significant concern with current GLP-1 therapies is the loss of lean muscle mass alongside fat. New combination approaches aim to address this:
- Bimagrumab, an anti-activin receptor antibody, is being studied in combination with GLP-1 agonists to preserve muscle during weight loss
- Myostatin inhibitors are in early-stage development as potential combination partners
Longer-Acting Formulations
Current weekly injections may eventually give way to less frequent dosing. Monthly and even less frequent formulations are in preclinical and early clinical development, which would reduce the treatment burden for patients on long-term therapy.
Expanded Indications
Beyond weight management and diabetes, GLP-1 therapies are being investigated for:
- Heart failure (STEP-HFpEF trials with semaglutide)
- Chronic kidney disease
- Non-alcoholic steatohepatitis (NASH)
- Alzheimer's disease and neurodegeneration
- Addiction and substance use disorders
What This Means for UK Patients
The UK's regulatory framework through the MHRA means new treatments typically become available within 12-18 months of pivotal trial results. NICE appraisals will determine NHS access. In the meantime, UK patients can expect continued improvements in existing treatments and increasing competition that may help drive down costs. MedsLens will track new approvals and pricing as these medications reach the UK market.